Tony Piscopio, OnKure Therapeutics CEO

OnKure Ther­a­peu­tics nabs $60M as HDAC in­hibitor awaits sol­id-tu­mor read­outs

OnKure Ther­a­peu­tics has lined up $60 mil­lion in a new pri­vate fund­ing round, adding to the Boul­der, CO, biotech’s bank ac­count as it works through …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.